38 results
424B3
MRZM
Marizyme, Inc.
16 Nov 23
Prospectus supplement
6:08am
. Currently, all of our revenue is generated from the sale of DuraGraft in European and Asian markets where the product had the required regulatory
424B3
MRZM
Marizyme, Inc.
17 Oct 23
Prospectus supplement
5:10pm
granted in the United States, Europe, Australia, India, Argentina, South Africa, Mexico, and several Asian countries.
Cardiac care is a large … its CE marking and existing distribution partners in select European and Asian countries resumed in the second quarter of 2022, with a targeted approach
8-K
EX-99.1
MRZM
Marizyme, Inc.
6 Oct 23
Regulation FD Disclosure
9:15am
, and several Asian countries.
With the FDA clearance achieved, the Company will now focus on executing its plan for US commercialization
8-K
EX-99.2
qxhls99g zi9eeh
10 May 23
Marizyme Announces IP Developments for DuraGraft® and its Pipeline Products
8:30am
8-K
EX-99.1
8ztldbhcr5he8y9vuxn
10 May 23
Marizyme Announces IP Developments for DuraGraft® and its Pipeline Products
8:30am
8-K
EX-99.1
lldpefrtlo4nuhwnv
5 Jan 22
Marizyme Announces Allowance of Patent Application for Flagship Product
4:33pm
8-K
EX-99.1
ljdjke
27 Dec 21
Marizyme Announces the Closing of My Health Logic
6:09am